Pathogenesis and treatment of systemic lupus erythematosus nephritis

Current Opinion in Rheumatology

Volumn 18, Issue 5, 2006, Pages 468-475

  Davidson, Anne ^a,b   Aranow, Cynthia ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NONE   (United States)

Author keywords

Biologic therapies; Biomarkers; Cytotoxic drugs; Mouse models; SLE nephritis

Indexed keywords

AZATHIOPRINE; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOGLOBULIN; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

CELL ACTIVATION; CLINICAL TRIAL; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MICE; MYCOPHENOLIC ACID; REMISSION INDUCTION;

EID: 33746927603     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000240356.45550.13     Document Type: Review

References (119)

1. Chowdhry IA, Kowal C, Hardin J, et al. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum 2005; 52:2403-2410.
2. Zhao Z, Weinstein E, Tuzova M, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005; 52:522-530.
3. Kalaaji M, Sturfelt G, Mjelle JE, et al. Critical comparative analyses of antialpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum 2006; 54:914-926.
4. Li QZ, Xie C, Wu T, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428-3439. Proteomic analysis of serum from SLE patients using a panel of glomerular antigens demonstrates that multiple autospecificities are present but only a subset of these correlate with nephritis.
5. Bagavant H, Fu SM. New insights from murine lupus: disassociation of autoimmunity and end organ damage and the role of T cells. Curr Opin Rheumatol 2005; 17:523-528.
6. Christensen SR, Kashgarian M, Alexopoulou L, et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202:321-331.
7. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14:19-24. This a review of pathogenic mechanisms of autoantibody deposition in the kidney.
8. Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005; 142:207-215.
9. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279:1052-1054.
10. Matsumoto K, Watanabe N, Akikusa B, et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 2003; 48:486-494.
11. Turnberg D, Cook HT. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens 2005; 14:223-228. This is an excellent review of the role of complement in kidney diseases and an overview of complement inhibitors being developed for clinical use.
12. Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114:679-688.
13. Horak P, Hermanova Z, Zadrazil J, et al. C1q complement component and - antibodies reflect SLE activity and kidney involvement. Clin Rheumatol 2005; 26:1-5.
14. Sinico RA, Radice A, Ikehata M, et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci 2005; 1050:193-200.
15. Wang Y, Hu Q, Madri JA, et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996; 93:8563-8568.
16. Bao L, Osawe I, Puri T, et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35:2496-2506.
17. Sesin CA, Yin X, Esmon CT, et al. Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney Int 2005; 68:110-120. High soluble levels of the endothelial protein C receptor, a marker of vasculopathy, are associated with nephritis and with serum creatinine.
18. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16:175-179. This paper describes a new type of SLE nephritis characterized by renal damage in the absence of inflammatory cells and immune complexes.
19. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639-1648.
20. Lewis EJ, Schwartz MM. Pathology of lupus nephritis. Lupus 2005; 14:31-38. This is an excellent review of the pathology of SLE nephritis including advantages and disadvantages of the new ISN2003 classification system.
21. Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003; 171:489-497.
22. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166:2913-2916.
23. Lauwerys BR, Wakeland EK. Genetics of lupus nephritis. Lupus 2005; 14:2-12. The authors provide an excellent review of the role of genetic polymorphisms in SLE nephritis.
24. Tarzi RM, Cook HT. Role of Fcgamma receptors in glomerulonephritis. Nephron Exp Nephrol 2003; 95:e7-e12.
25. Zhu LJ, Liu ZH, Zeng CH, et al. Association of interleukin-10 gene -592 A/C polymorphism with the clinical and pathological diversity of lupus nephritis. Clin Exp Rheumatol 2005; 23:854-860.
26. Miyazaki T, Ono M, Qu WM, et al. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol 2005; 35:1510-1520.
27. Reddy MV, Johansson M, Sturfelt G, et al. The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1. Genes Immun 2005; 6:658-662.
28. Johansson M, Arlestig L, Moller B, Rantapaa-Dahlqvist S. Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 2005; 52:1665-1669.
29. Parsa A, Lovett DH, Peden EA, et al. Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun 2005; 6:217-224.
30. Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851-855. This paper describes a novel mechanism by which copy number polymorphism of the Fcγ3B receptor can cause an increased inflammatory response.
31. Lee YH,Harley JB, Nath SK.Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 2006; 14:364-371.
32. Nath SK, Harley JB, Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005; 118:225-234. This is a metaanalysis of the association of polymorphisms of CR1 and IL-10 in SLE.
33. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54:421-432. These are important guidelines for future trials of lupus nephritis.
34. Chan TM. Preventing renal failure in patients with severe lupus nephritis. Kidney Int Suppl 2005; (94):S116-S119.
35. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005; 14:1-8. This is a review of the utility of the new ISN nephritis classification criteria.
36. Yokoyama H, Wada T, Hara A, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66:2382-2388.
37. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50:3934-3940.
38. Calguneri M, Ozbalkan Z, Ozturk MA, et al. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol 2006; Mar 18 [Epub ahead of print].
39. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119:355.e25-33. This describes long term outcome and predictors of response to cyclophosphamide in a large group of patients with lupus nephritis. Treatment with higher cumulative doses of cyclophosphamide and achievement of remission were associated with improved outcomes.
40. Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14:265-272. This was a long-term study of response to oral cyclophosphamide followed by azathioprine. Baseline renal scarring and an inability to achieve a complete remission were predictors of a poorer outcome.
41. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl JMed 2005; 353:2219-2228. This large open label study comparing intravenous cyclophosphamide with mycophenolate mofetil for nephritis remission induction showed increased efficacy of mycophenolate and better tolerability.
42. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10:504-510. This was a randomized study comparing intravenous cyclophosphamide to mycophenolate mofetil.
43. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156-1162.
44. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076-1084. This is the long term follow-up with additional subjects added to the first randomized study comparing cyclophosphamide to mycophenolate mofetil for lupus nephritis.
45. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971-980.
46. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14 (Suppl 1):s33-s38. This was an expanded long term follow-up of the initial study of maintenance therapy with mycophenolate mofetil, azathioprine or quarterly intravenous cyclophospohamide following remission by cyclophosphamide.
47. Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23:873-876.
48. Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44:1317-1321.
49. Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66:2411-2415.
50. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559-2568.
51. McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005; 353:2282-2284.
52. Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005; 14:49-52. This is an excellent review of renal flares occurring after remission of lupus nephritis.
53. Fujinaga S, Kaneko K, Ohtomo Y, et al. Induction therapy with lowdose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol 2005; 20:1500-1503.
54. Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68:813-817.
55. Tam LS, Li EK, Wong CK, et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 2006; 65:417-418.
56. Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005; 64:153-155.
57. Tse KC, Li FK, Tang S, et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005; 14:947-952. This describes a study of the beneficial effects of angiotensin inhibition or receptor blockade on proteinuria in patients with inactive lupus nephritis.
58. Daza L, Kornhauser C, Zamora L, Flores J. Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients. Prostaglandins Other Lipid Mediat 2005; 78:194-201.
59. Kanda H, Kubo K, Tateishi S, et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14:288-292. This is the first published report of the effects of angiotensin receptor blockade on proteinuria in lupus nephritis.
60. Mor A, Bingham C 3rd, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005; 32:740-743.
61. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 2005; 14:13-18. This is the first published report of the short term use of a TNFα antagonist for severe SLE.
62. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29:219-228.
63. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005; 66:395-402.
64. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326:1373-1379.
65. Stummvoll GH, Aringer M, Smolen JS, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005; 64:1015-1021.
66. Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005; 52:371-377.
67. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17:550-557. This is an excellent review of all the open label studies of rituximab in SLE patients of whom approximately 50% had nephritis.
68. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50:3580-3590.
69. Peterson KS, Huang JF, Zhu J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004; 113:1722-1733.
70. Liu J, Karypis G, Hippen KL, et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 2006; 7:156-168. This describes the first study using microarray analysis to examine kidneys of several SLE mouse models.
71. Oates JC, Varghese S, Bland AM, et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int 2005; 68:2588-2592. This discovery-based proteomic study identified a number of proteins expressed in the urine of SLE patients.
72. Schmid H, Henger A, Kretzler M. Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15:123-129. This is a state of the art review of discovery-based methods for analysis of renal disease.
73. Chan RW, Lai FM, Li EK, et al. Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology (Oxford) 2006; Feb 3 [Epub ahead of print].
74. Chan RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48:1326-1331.
75. Avihingsanon Y, Phumesin P, Benjachat T, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006; 69:747-753.
76. Chan RW, Lai FM, Li EK, et al. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 2006; Jan 31 [Epub ahead of print]. This study examined several inflammatory mediators in the urine sediment of SLE patients using PCR methodology and showed that the transcription factor T-bet is expressed in the urine of patients with proliferative glomerulonephritis.
77. Noris M, Bernasconi S, Casiraghi F, et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73:804-809.
78. Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49:761-767.
79. Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16:467-473.
80. Rovin BH, Song H, Hebert LA, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005; 68:1825-1833.
81. Chan RW, Lai FM, Li EK, et al. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2004; 50:2882-2890.
82. Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003; 48:2555-2566.
83. Balboni I, Chan SM, Kattah M, et al. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 2006; 24:391-418. This is a state of the art review of multiplexed proteomic technology.
84. Wiesendanger M, Stanevsky A, Kovsky S, Diamond B. Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:227-235. This is an excellent review of potential new therapies for SLE.
85. Ehlers M, Fukuyama H, McGaha TL, et al. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203:553-561. This paper shows that in one mouse model of SLE, TLR9 deficiency abrogates the anti-DNA response without altering the protective immune response to a foreign antigen.
86. Scalapino KJ, Tang Q, Bluestone JA, Daikh DI. Suppression of murine lupus by adoptive transfer of exogenously expanded thymic derived regulatory T-cells in NZB/W mice. Arthritis Rheum 2005; 52 (9 Supplement):S625.
87. Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005; 174:3247-3255. Low doses of peptides derived from histones can result in a marked delay of disease onset in SNF1 mice by a mechanism that involves induction of regulatory T cells.
88. Shimizu S, Sugiyama N, Masutani K, et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005; 175:7185-7192. In MRL/lpr mice the absence of IFNγ results in switching of the nephritis phenotype from proliferative to membranous.
89. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173:2134-2142.
90. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006; 54:336-342. This paper shows that TLR9 deficiency exacerbates disease in the MRL/lpr model.
91. Amital H, Heilweil M, Ulmansky R, et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005; 175:5516-5523.
92. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724-734. This is a mechanistic paper in mice that shows the mechanism of action of BAFF blockade and the differences between blockade of BAFF alone and blockade of both BAFF and APRIL.
93. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307:590-593. This paper shows that restoration of normal expression of the inhibitory FcRIIB receptor prevents disease in mice that have constitutively low levels of this receptor on their B cells.
94. Inoue A, Hasegawa H, Kohno M, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52:1522-1533.
95. de Lema GP, Maier H, Franz TJ, et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005; 16:3592-3601.
96. Anders HJ, Belemezova E, Eis V, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004; 15:1504-1513.
97. Sadanaga A, Nakashima H, Masutani K, et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 2005; 52:3987-3996.
98. Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11:933-935.
99. Barber DF, Bartolome A, Hernandez C, et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 2006; 176:589-593.
100. Schwarting A, Paul K, Tschirner S, et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005; 16:3264-3272. This shows a robust effect on IFNb in the MRL/lpr model.
101. Patole PS, Zecher D, Pawar RD, et al. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005; 16:3273-3280.
102. Rodriguez W, Mold C, Marnell LL, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006; 54:325-335.
103. Werwitzke S, Trick D, Kamino K, et al. Inhibition of lupus disease by antidouble-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum 2005; 52:3629-3638. This paper shows that natural autoantibodies can protect against SLE nephritis.
104. Watanabe H, Mamelak AJ, Weiss E, et al. Antivascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res 2005; 11:407-409.
105. Ma L, Chan KW, Trendell-Smith NJ, et al. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol 2005; 35:3364-3375.
106. Patole PS, Grone HJ, Segerer S, et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16:1326-1338.
107. Pawar RD, Patole PS, Zecher D, et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17:141-149.
108. Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174:2499-2506.
109. Anders HJ, Vielhauer V, Schlondorff D. Current paradigms about chemokines as therapeutic targets. Nephrol Dial Transplant 2004; 19:2948-2951.
110. Vielhauer V, Eis V, Schlondorff D, Anders HJ. Identifying chemokines as therapeutic targets in renal disease: lessons from antagonist studies and knockout mice. Kidney Blood Press Res 2004; 27:226-238.
111. Wang X, Huang W, Mihara M, et al. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002; 168:2046-2053.
112. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175:8392-8400.
113. Bagavant H, Tung KS. Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J Immunol 2005; 175:944-950.
114. La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004; 173:3542-3548.
115. Jorgensen TN, Gubbels MR, Kotzin BL. New insights into disease pathogenesis from mouse lupus genetics. Curr Opin Immunol 2004; 16:787-793.
116. Singh RR, Saxena V, Zang S, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003; 170:4818-4825.
117. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197:777-788.
118. Li J, Liu Y, Xie C, et al. Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum 2005; 52:3063-3072.
119. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006; 354:1667-1669. This is an important paper that stresses the flaws in post-hoc subgroup analysis of clinical trials.